Iskalni niz je ali predolg ali pa vsebuje preveč besed.
Prevodi: sl > en
1–6/6
EMR
1 Prevajalska redakcija
RS
EMEA
• EMR 62 202- 047:
• EMR 62 202-047:
2 Prevajalska redakcija
RS
EMEA
• EMR 62 202- 006:
• EMR 62 202-006:
3 Prevajalska redakcija
RS
EMEA
• EMR 62 202- 002:
• EMR 62 202-002:
4 Prevajalska redakcija
RS
EMEA
Analiza ni bila mogoča samo v študiji EMR 62 202- 007.
Only in study EMR 62 202-007, an analysis was not possible.
5 Prevajalska redakcija
RS
EMEA
• EMR 62 202- 007: v tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom po neuspešnem zdravljenju metastatske bolezni z irinotekanom kot zadnjem zdravljenjem pred vstopom v študijo primerjali kombinacijo cetuksimaba in irinotekana (218 bolnikov) s samostojnim cetuksimabom (111 bolnikov).
• EMR 62 202-007: This randomised study in patients with metastatic colorectal cancer after failure of irinotecan-based treatment for metastatic disease as the last treatment before study entry compared the combination of cetuximab and irinotecan (218 patients) with cetuximab monotherapy (111 patients).
6 Prevajalska redakcija
RS
EMEA
• EMR 62 202- 013: v tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom, ki še niso bili zdravljeni zaradi metastatske bolezni, primerjali kombinirano terapijo s cetuksimabom in irinotekanom ter infundiranim 5- fluorouracil/ folinsko kislino (5- FU/ FA (599 bolnikov) z enako kemoterapijo v monoterapiji.
• EMR 62 202-013: This randomised study in patients with metastatic colorectal cancer who had not received prior treatment for metastatic disease compared the combination of cetuximab and irinotecan plus infusional 5-fluorouracil/ folinic acid (5-FU/ FA) (599 patients) to the same chemotherapy alone (599 patients).
Prevodi: sl > en
1–6/6
EMR